SCHEMBL21669302

SCHEMBL21669302

COC(O)C(NC(C)=O)c1ccc(OC(=O)CCS(=O)(=O)OC)cc1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.41
ALDH1A1 P00352 2/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ESR1 P03372 1/20 0.34
HIF1A Q16665 1/20 0.34
ACACB O00763 7/20 0.33
MEN1 O00255 1/20 0.33
RAB9A P51151 1/20 0.33
CNR1 P21554 1/20 0.33
OPRK1 P41145 1/20 0.33
BCL9 O00512 1/20 0.32
CTNNB1 P35222 1/20 0.32
ACACA Q13085 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21669212 0.91 KMT2A (0.43) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL24282722 0.90 KMT2A (0.39) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL21669311 0.90 KMT2A (0.42) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL21669217 0.86 KMT2A (0.40) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL24282828 0.86 ALDH1A1 (0.36) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL21669236 0.83 CA1 (0.43) KMT2AALDH1A1LMNAMEN1
SCHEMBL21669328 0.82 KMT2A (0.40) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL21669358 0.81 KMT2A (0.42) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL21669357 0.81 KMT2A (0.41) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL21669220 0.79 KMT2A (0.45) KMT2AALDH1A1LMNAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3829568-B1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS ALZHEON INC (US) 2023-09-06 EP disclosed
US-20220087967-A1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS ALZHEON, INC. 2022-03-24 US disclosed
WO-2020028348-A1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS ALZHEON, INC. (US) 2020-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220087967-A1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS PSEN1, APP, PSEN2 KMT2A 3892/4885ALDH1A1 591/4885LMNA 4021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.